Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis

Glioblastoma Multiforme (GBM) is the most common and aggressive form of intracranial tumors with poor prognosis. In recent years, tumor immunotherapy has been an attractive strategy for a variety of tumors. Currently, most immunotherapies take advantage of the adaptive anti-tumor immunity, such as c...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 11; p. 593219
Main Authors Hu, Jinyang, Xiao, Qungen, Dong, Minhai, Guo, Dongsheng, Wu, Xudong, Wang, Baofeng
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 27.11.2020
Subjects
CD47-SIRPα
glioblastoma
glioblastoma microenvironment
immune checkpoint
Immunology
tumor-associated macrophages/microglia
glioblastoma microenvironment
glioblastoma
CD47-SIRPα
tumor-associated macrophages/microglia
immune checkpoint
Online AccessGet full text

Cover

More Information
Summary:Glioblastoma Multiforme (GBM) is the most common and aggressive form of intracranial tumors with poor prognosis. In recent years, tumor immunotherapy has been an attractive strategy for a variety of tumors. Currently, most immunotherapies take advantage of the adaptive anti-tumor immunity, such as cytotoxic T cells. However, the predominant accumulation of tumor-associated microglia/macrophages (TAMs) results in limited success of these strategies in the glioblastoma. To improve the immunotherapeutic efficacy for GBM, it is detrimental to understand the role of TAM in glioblastoma immunosuppressive microenvironment. In this review, we will discuss the roles of CD47-SIRPα axis in TAMs infiltration and activities and the promising effects of targeting this axis on the activation of both innate and adaptive antitumor immunity in glioblastoma.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Jian Wang, University of Bergen, Norway
Reviewed by: Xuyao Zhang, Fudan University, China; Pengfei Ge, Jilin University, China
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2020.593219